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Background: Previous studies have demonstrated the potential beneficial effect of 
N- acetylcysteine (NAC) in chronic obstructive pulmonary disease (COPD). However, the 
required dose and responder phenotype remain unclear. The current study investigated the effect 
of high-dose NAC on airway geometry, inflammation, and oxidative stress in COPD patients. 
Novel functional respiratory imaging methods combining multislice computed tomography 
images and computer-based flow simulations were used with high sensitivity for detecting 
changes induced by the therapy.
Methods: Twelve patients with Global Initiative for Chronic Obstructive Lung Disease stage II 
COPD were randomized to receive NAC 1800 mg or placebo daily for 3 months and were then 
crossed over to the alternative treatment for a further 3 months.
Results: Significant correlations were found between image-based resistance values and 
 glutathione levels after treatment with NAC (P = 0.011) and glutathione peroxidase at baseline 
(P = 0.036). Image-based resistance values appeared to be a good predictor for glutathione 
peroxidase levels after NAC (P = 0.02), changes in glutathione peroxidase levels (P = 0.035), 
and reduction in lobar functional residual capacity levels (P = 0.00084). In the limited set of 
responders to NAC therapy, the changes in airway resistance were in the same order as changes 
induced by budesonide/formoterol.
Conclusion: A combination of glutathione, glutathione peroxidase, and imaging parameters 
could potentially be used to phenotype COPD patients who would benefit from addition of 
NAC to their current therapy. The findings of this small pilot study need to be confirmed in a 
larger pivotal trial.
Keywords: functional respiratory imaging, computational fluid dynamics, computed 
 tomography, chronic obstructive pulmonary disease, N-acetylcysteine
Introduction
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder charac-
terized by dysfunction of the small and large airways, as well as destruction of the 
lung parenchyma and its vasculature in highly variable combinations. The hallmark 
of COPD is expiratory flow limitation, which is slowly progressive and irreversible.1–3 
There is also increasing evidence that the inflammatory processes of COPD are closely 
associated with oxidative stress. Proinflammatory cytokines and growth factors 
stimulate production of reactive oxygen species. The resulting imbalance between 
oxidants and antioxidants triggers signaling cascades for a variety of transduction 
pathways and gene expression, leading in turn to altered expression of proinflam-
matory  factors.  Neutrophils are key cells in the inflammatory response in COPD. 
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Excessive  transmigration into the lung tissues and abnormal 
activation are largely responsible for overproduction of 
reactive oxygen species and release of proteolytic enzymes 
in the lungs.
N-acetylcysteine (NAC) is a glutathione precursor with 
beneficial properties. It is a source of sulfhydryl groups in 
cells and increases the level of reduced glutathione. Reduced 
glutathione serves as a reducing agent by forming intermo-
lecular disulfide nonradical end product-oxidized glutathione. 
NAC is also a scavenger of free radicals as it interacts with 
reactive oxygen species, such as the hydroxyl radical (OH-) 
and hydrogen peroxide (H
2
O
2
).4–7
In COPD patients, NAC has been used as a mucolytic 
and for its antioxidant properties. In a large-scale study, it 
was not possible to demonstrate that NAC decreases the 
decline in forced expiratory volume in one second (FEV
1
) in 
COPD patients after a period of 3 years.8 In the same study, 
however, there were some preliminary indications that NAC 
reduce hyperinflation, since a decrease in functional residual 
capacity was observed over time. However, the effects of 
NAC are certainly dose-dependent.9 It might well be that 
the lack of efficacy is partially explained by use of dosages 
that are too low.9
Considering all the above, it would be worthwhile to study 
the effect of higher dosages of NAC on the small airways, 
inflammation, and oxidative stress in COPD patients. In this 
randomized crossover study, patients with Global initiative 
for chronic Obstructive Lung Disease (GOLD) stage II 
COPD received placebo for 3 months and NAC at a dosage 
of 600 mg 3 times daily for 3 months in addition to their usual 
medication. For this trial, we used novel advanced imaging 
tools that have been demonstrated in the past to yield more 
sensitive outcome parameters compared with classical lung 
function tests.10 This functional respiratory imaging method 
was validated in previous studies using gamma scintigra-
phy,11,12 single photon emission computed tomography (CT),13 
and hyperpolarized 3He magnetic resonance imaging.14 
Subsequently, this method was used to assess the effect of 
a long-acting β
2
-agonist,15 a combination of a long-acting 
β
2
-agonist and inhaled corticosteroid,10 and a short-acting 
anticholinergic and short-acting β
2
-agonist.16 In the current 
study, we hypothesized that this method could be used to gain 
additional insight into the mode of action of NAC in COPD 
patients, particularly the relationship between upregulation 
of glutathione/glutathione peroxidase and changes in airways 
volume and resistance. Further, this pilot study aimed to 
provide a basis for identifying patient phenotypes that would 
benefit most from NAC therapy.
Materials and methods
The study was conducted according to all ethical principles. 
Approval was obtained from the ethics committee and all 
patients gave their informed consent (NCT00969904). The 
study started in August 2009 and ended in June 2012.
Patient population
Twelve COPD patients (nine men and three women) were 
included. To be eligible for the study, patients had to have 
documented COPD and meet the following inclusion crite-
ria: a smoking history of at least 10 pack-years; compatible 
symptoms, including dyspnea, cough, and sputum produc-
tion; a decreased Tiffeneau index (FEV
1
/forced vital capac-
ity [FVC]) , 0.7; age $40 years; cessation of smoking 
for at least one month; moderate to severe COPD with an 
FEV
1
 30%–80% of predicted [GOLD stages II and III]; and 
treatment according to GOLD guidelines. The following 
exclusion criteria were applied: exacerbation during the last 
8 weeks; allergy to acetylcysteine or to another element of 
the product; phenylketonuria; untreated active peptic ulcer; 
renal and/or cardiac insufficiency; previous treatment with 
NAC for more than 6 months or during the last 3 months; 
ongoing treatment with oral, intravenous, or intramuscular 
corticosteroids; pregnancy or breast-feeding; and treatment 
with an orally administered cephalosporin.
study design
At all visits, patients received full lung function testing yielding 
the following parameters: FEV
1
, FEV
1
/FVC, peak expiratory 
flow from spirometry, and airway resistance (Raw) and specific 
airway resistance from body plethysmography. A low-dose 
multislice CT scan was taken at total lung capacity and func-
tional residual capacity. From these images of the airways, 
lung and lobar volumes could be obtained as well as airway 
resistance values by means of computational fluid dynamics. 
In addition, a blood sample was taken to measure levels of 
glutathione, glutathione peroxidase, superoxide dismutase, and 
interleukin-8. Patients completed the Saint George’s Respira-
tory Questionnaire (SGRQ, Table 1). At the first visit, patients 
were randomized according to a computer-generated ran-
domization list to treatment with NAC (Fluimucil®,  Zambon 
SpA, Bresso, Italy) at a dose of 600 mg three times daily or 
placebo in addition to their usual treatment. After 3 months 
of treatment, the patients returned to the hospital for further 
tests and were crossed over to NAC or placebo. After a further 
3 months, all measurements were repeated.
To limit exposure to ionizing radiation, a dose reduction 
protocol was used for the CT scans. A VCT light speed  scanner 
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Table 1 Flowchart describing visits and tests
Weeks -2 0 12 24
Visit 1 2 5 8
Screening Baseline start  
treatment A
Stop treatment A,  
start treatment B
End of  
treatment
Informed consent X
Inclusion/exclusion criteria X
Physical examination X X
Monitoring current therapy X
Medical history X
spirometry X X X X
nO X X X
Body plethysmography X X X
Diffusion X X X
aBg X X X
eBC X X X
low-dose multislice CT thorax X X X
Blood collection and vital signs X X X
sgrQ X X X
Abbreviations: sgrQ, st george’s respiratory Questionnaire; aBg, arterial blood gas; eBC, exhaled breath condensate; CT, computed tomography; nO, nitric oxide.
with 64 detector rows (General Electric, Fairfield, CT, USA) 
was used. The multislice CT settings were as  follows: tube 
voltage, 120 kV; tube current,10–100 mA; noise factor, 28; 
collimation, 0.625 mm; rotation time, 0.6 seconds; and pitch 
factor, 1.375. The resulting radiation dose was in the order 
of 1–2 mSv per scan. Images were reconstructed to a slice 
thickness of 0.6 mm. Digital Imaging and Communications 
in Medicine (DICOM) images were assessed using a com-
mercially available software package approved by the US 
Food and Drug Administration  (Mimics, Materialise, Leuven, 
Belgium). The tracheobronchial tree was subsequently seg-
mented using a semiautomatic approach. A total of three 
airway models were obtained per patient, ie, a baseline model, 
a model after 3 months of treatment with NAC or placebo, 
and a repeat model 3 months after crossover from NAC or 
placebo. After segmentation, all models for the same patient 
were superimposed using a least squares method to ensure 
that a comparison was possible between the different geom-
etries. Segmentation yields the airway volumes at the central 
(iVaw
cent
) and distal (iVaw
dist
) levels. In addition to airway 
volumes, it was also possible to extract the lung and lobar 
volumes from the CT images at functional residual capacity 
and total lung capacity. Using computational fluid dynamics, 
it is possible to describe the flow patterns inside the airways 
based on computer simulation. Computational fluid dynamics 
numerically solves the Navier–Stokes equations inside the pre-
scribed flow domain, in this case the airway tree structures at 
different measurement points. The main outcome parameter of 
computational fluid dynamic calculations is airway resistance 
in the central (iRaw
cent
) and distal airways (iRaw
dist
).
statistical analysis
Statistical analysis was performed using Statistica 9.1 soft-
ware (StatSoft Inc, Tulsa, OK, USA). Differences were 
assessed using the Wilcoxon matched-pairs test for equal 
sample sizes that are related or Mann–Whitney U test for 
independent samples. Correlations were assessed using the 
Spearman’s rank test. A P-value , 0.05 was considered to 
be statistically significant.
Results
Patients
All patients were categorized by GOLD guidelines as stage II 
with an average post-bronchodilation FEV
1
 of 65.38% ± 7.12% 
predicted. The average age of the patients was 65.00 ± 9.63 
years, average height was 171.17 ± 8.27 cm, and the average 
smoking history was 56.16 ± 33.12 pack-years (Table 2).
Image-based resistance and volume
Figure 1 shows image-based resistance (iRaw) and volume 
(iVaw) measurements for the individual patients. The left 
hand side depicts iRaw, while the right hand side shows iVaw. 
The left upper quadrant indicates an increase in iRaw, hence 
nonresponders. The left lower quadrant indicates a decline in 
iRaw, hence responders. For iVaw it is reversed, whereby the 
right upper quadrant indicates an increase in iVaw, therefore 
identifying responders, and the right lower quadrant indicates 
an decline in iVaw, hence nonresponders. From Figure 1, 
it can be seen that there was a relatively even distribution 
between patients who responded in terms of iRaw and iVaw 
measurements. There were six patients with a reported 
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Table 2 Patient characteristics at baseline
Age, years Height  
(cm)
Pack-years FEV1  
(L)
FEV1 
(% predicted)
FEV1/FVC  
(%)
TLC  
(% predicted)
RV  
(% predicted)
Males 
(n = 9)
66.0 ± 10.0 172.7 ± 8.8 62.5 ± 35.2 2.0 ± 0.3 66.0 ± 8.0 57.0 ± 6.2  97.8 ± 13.3 118.8 ± 30.7
Females 
(n = 3)
62.0 ± 9.5 166.7 ± 4.7 37.1 ± 18.4 1.6 ± 0.3 63.5 ± 4.1 56.4 ± 11.0 114.0 ± 14.5 147.3 ± 22.1
Abbreviations: TlC, total lung capacity; FeV, forced expiratory volume in one second; FVC, forced vital capacity; rV, residual volume.
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Figure 1 Changes in iraw and iVaw for all patients. 
Abbreviations: iraw, image-based resistance; iVaw, image-based volume.
reduction in iRaw
cent
 and four with a reported reduction in 
iRaw
dist
. In total, five patients demonstrated an increase in 
iVaw
dist
 and three patients showed an increase in iVaw
cent
. In 
general, the changes could be considered small. However, the 
differences are considerable for individual patients on a local 
scale.  Figure 2 shows the changes in airway resistance after 
placebo and NAC treatment for a patient who could be con-
sidered an iRaw or NAC responder. It could be observed that 
the changes are not homogeneously distributed throughout 
the airway system with a general decline in airway resistance 
up to 50% after NAC treatment and an increase in airway 
resistance up to 20% after placebo. Figure 3 shows the results 
for a nonresponder in terms of iRaw after NAC treatment. It 
could be observed that local resistance tended to increase up 
to 20% both after placebo and after NAC treatment.
glutathione peroxidase and glutathione
The study showed a significant correlation (R = -0.7, 
P = 0.011) between the level of glutathione after NAC 
treatment and the change in resistance of the central airways 
(iRaw
cent
) measured using imaging and computational fluid 
dynamics (Figure 4). No correlation was found between 
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iRaw changes after 3 months of NAC treatment [%]
iRaw changes after 3 months of placebo treatment [%]
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Figure 2 Changes in iraw after 3 months of treatment with naC (top) and placebo 
(bottom) in iraw responders. 
Abbreviations: naC, n-acetylcysteine; iraw, image-based resistance.
glutathione after placebo and iRaw
cent
 after placebo. The level 
of glutathione peroxidase at baseline (R = 0.61, P = 0.036) 
and after placebo treatment (R = 0.67, P = 0.017) correlated 
with the change in distal airway resistance (iRaw
dist
) after 
NAC treatment (Figure 5). No significant correlation was 
found between the baseline and placebo values for gluta-
thione peroxidase and the change in iRaw
dist
 after placebo. 
Using the Mann–Whitney U test, it could be observed that 
the level of glutathione after treatment was significantly 
higher (P = 0.020) in patients who demonstrated a reduction 
in iRaw
cent
 compared with patients in whom iRaw
cent
 stayed 
constant or increased (Figure 6). A similar result was found 
based on the segmented airway volume of the central airways 
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Figure 3 Changes in iraw after 3 months of treatment with naC (top) and placebo 
(bottom) in an iraw nonresponder. 
Abbreviations: naC, n-acetylcysteine; iraw, image-based resistance.
(iVaw
cent
). Glutathione after NAC treatment was significantly 
higher (P = 0.042) in patients with an increase in iVaw
cent
. 
In patients who demonstrated a reduction in total (central + 
distal) image-based airway resistance (iRaw
tot
), the change 
in glutathione peroxidase was significantly (P = 0.035) 
higher compared with patients in whom iRaw
tot
 did increase. 
On average, glutathione peroxidase levels increased in the 
group with reduced iRaw
tot
 and decreased in the group 
with elevated iRaw
tot
 after treatment. FEV
1
 also increased 
slightly in the group with reduced iRaw
tot
 and decreased in 
the group with higher iRaw
tot
 after NAC treatment, although 
the difference between the two groups was not significant 
(Figure 7).
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Figure 4 Significant correlation between change in computational fluid dynamics-based resistance of the central airways, iRawcent, and glutathione levels after naC treatment. 
Abbreviations: iraw, image-based resistance; gsh, glutathione; naC, n-acetylcysteine.
Hyperinflation
For patients in whom iRaw
dist
 decreased, hyperinflation 
in terms of lobar functional residual capacity level also 
decreased (Figure 8). For patients in whom iRaw
dist
 did 
not decrease, the median lobar functional residual capac-
ity level increased. The difference between the two groups 
was significant (P = 0.00084). Two patients experienced a 
reduction in iRaw
dist
 larger than 0.002 kPa/L. The Wilcoxon 
matched-pairs test showed a significant improvement in 
lobar inspiratory capacity (lobar total lung capacity – lobar 
functional residual capacity) in these patients compared with 
baseline (P = 0.028) and placebo (P = 0.011). A significant 
decline in lobar inspiratory capacity was observed between 
baseline and placebo (P = 0.011, Table 3). The SGRQ symp-
tom score also improved in these two patients.
Discussion
This study aimed to assess the effect of high-dose NAC on 
image-based airway and lung geometry, inflammation, and 
oxidative stress in patients with moderate COPD. Previous 
studies10,16 have demonstrated that functional respiratory imag-
ing can detect changes that are not reflected in conventional 
pulmonary function tests. Significant correlations were found 
between imaging parameters and markers related to oxidative 
stress. The initial results of this placebo-controlled, crossover 
trial could assist in gaining further insight into the effect of 
NAC and selection of potential responders.
The effect of NAC in COPD patients has been the subject 
of many clinical trials in the past. The capability of NAC to 
increase levels of reduced glutathione and hence to enhance 
protection against oxidative stress has been clearly demon-
strated in preclinical studies.17–19 Nevertheless, it has been 
difficult to demonstrate consistently the added clinical value 
of NAC in COPD patients. Reasons often cited for this are the 
relatively small size of the clinical trials and variation in the 
dose of NAC used in the trials.20 Positive effects of NAC dem-
onstrated in previous trials include a reduction in air trapping 
and subsequent improvement in inspiratory capacity.21 Also, 
a reduction in the hazard ratio for exacerbations was reported 
in BRONCUS (Bronchitis Randomized on N-acetylcysteine 
(NAC) Cost-Utility Study),8 potentially due to enhanced 
protection against viral infections.20 The use of lung function, 
and especially FEV
1
, to establish the effect of NAC, which 
is not a bronchodilator, has been challenging because FEV
1
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Figure 5 Significant correlation between change in computational fluid dynamics-based resistance of the distal airways iRawdist and level of gPx at baseline (top) and after 
placebo (bottom). 
Abbreviations: iraw, image-based resistance; gPx, glutathione peroxidase.
is a poor predictor of clinical symptoms, exercise tolerance, 
and response to bronchodilators in COPD.21–23
Our placebo-controlled, crossover study, for the first 
time, uses novel imaging tools with a higher sensitivity 
to detect changes in the respiratory system induced by 
high-dose NAC. Previous studies have validated and dem-
onstrated the capabilities of these new methods to show 
changes induced by short-acting and long-acting broncho-
dilators and anti-inflammatory compounds. Interestingly, 
even despite the small sample size, the current study was 
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Figure 6 Glutathione after NAC treatment was significantly different for patients who experienced a decrease in iRawcent (top) and an increase in iVawcent (bottom). 
Abbreviations: iraw, image-based resistance; gsh, glutathione; iVaw, image-based volume.
able to show correlations between image-based parameters 
(ie, computational fluid dynamics-based resistance) and 
the enzyme glutathione peroxidase, which protects against 
oxidative stress, and the antioxidant glutathione. Both the 
enzyme and the antioxidant are known to be affected by 
NAC. To put these results into perspective, it is useful to 
compare the changes in central and distal airway resis-
tance as measured by the CT/computational fluid dynam-
ics combination with changes previously reported in our 
other imaging trials. It could be observed that for patients 
responding well to NAC, the magnitude of the reduction 
in airway resistance was in the same order as the effect 
induced by 320/90 µg budesonide/formoterol combination10 
and just below the maximum effect of 400 µg of salbuta-
mol and 80 µg of ipratropium bromide.16 As in previous 
studies, the placebo group also demonstrated in general an 
increase in airway resistance which indicates that, despite 
the lack of clear evidence, COPD patients need to use their 
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Figure 7 Significant difference in change in GPx between responders and nonresponders in terms of iRawtot (top) and no significant difference in change in GPx between 
responders and nonresponders in terms of FeV1 (bottom). 
Abbreviations: iraw, image-based resistance; gPx, glutathione peroxidase; FeV1, forced expiratory volume in one second.
inhalation medication consistently to limit the decline in 
lung function.
The role of glutathione peroxidase appears to be 
 interesting. The current study clearly shows a correlation 
between the baseline and placebo values for glutathione 
peroxidase and the change in resistance after treatment. 
It is known that the biochemical function of glutathione 
peroxidase is to reduce free H
2
O
2
 to water, thereby protect-
ing the organism from oxidative stress. We could speculate 
that patients with low baseline glutathione peroxidase have 
additional reserves that could be activated by high doses of 
NAC, eventually resulting in a reduction in airway resistance. 
This hypothesis needs to be investigated further in a larger 
clinical trial in which the role of cytokines, not studied in the 
current trial, could also be explored further. If the hypothesis 
is confirmed, the level of glutathione peroxidase could be the 
basis for selecting patients who would benefit from treatment 
with NAC in addition to their current therapy.
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Figure 8 Significant difference in reduction of hyperinflation (lobar FRC volumes) between responders and nonresponders in terms of iRawdist. 
Abbreviations: iraw, image-based resistance; FrC, forced residual capacity.
Table 3 Lobar inspiratory capacity decreased significantly after 
placebo and increased after treatment with naC in patients with 
a reduction in irawdist , 0.002 kPa/l
Baseline After placebo After NAC
Inspiratory capacity (l)  
on lobe level  
(TlC-FrC)
0.63 ± 0.27 0.59 ± 0.26 0.65 ± 0.28
Mann–Whitney U test  
with baseline, P-value
– 0.011 0.028
Mann–Whitney U test  
with placebo, P-value
0.011 – 0.011
Abbreviations: naC, n-acetylcysteine; TlC, total lung capacity; FrC, functional 
residual capacity; iraw, image-based resistance.
Further, the current pilot study demonstrated that FEV
1
 
was not a good predictor for changes in glutathione peroxi-
dase induced by NAC therapy. The iRaw
dist
 on the other hand 
was able to group patients according to the difference in 
glutathione peroxidase with statistical significance. The lat-
ter can be explained by the enhanced signal-to-noise ratio of 
imaging. By focusing on a specific clinically relevant region, 
ie, the central and distal airways, it is possible to eliminate 
“noise” from the upper airway and the patient’s effort. How-
ever, the spirometer’s inherent black box approach does not 
allow this. In line with previous studies, it was demonstrated 
that NAC could have a beneficial effect on hyperinflation in 
a subset of patients. The functional residual capacity level 
of the lobes was significantly reduced in patients showing a 
decrease in distal airway resistance. Inspiratory capacity at 
a lobar level was improved in the best iRaw
dist
 responders. 
Even though this was only in two patients, the improvement 
in SGRQ symptom score potentially indicates a beneficial 
effect of reduction in hyperinflation on the patient’s quality 
of life. Recent large-scale studies also point in the same 
direction, whereby hyperinflation appears to be an important 
determinant of the patient’s clinical condition.24,25
The current pilot study demonstrates how new imaging 
tools can assist research into the pathophysiology of COPD 
and the subsequent effect of inhalation therapies. However, the 
sample size of the current study was very small and the results 
need to be confirmed in larger clinical trials.  Nonetheless, 
there is increasing evidence that these novel imaging methods 
could complement existing pulmonary function tests and 
patient-reported outcome parameters to provide better phe-
notyping of COPD patients in order to enhance and expedite 
future development of respiratory drugs.
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